Novartis has gotten new evidence from the CHAMP-HF registry comparing Entresto patients to patients not taking Entresto, which showed that chronic heart failure (HF) patients with reduced ejection fraction (HFrEF) taking Entresto reported early, statistically significant improvement in health status, as measured by the KCCQ-12 overall summary score (KCCQ-OS).
Novartis said that this finding was driven by statistically significant improvements in symptom frequency and quality of life domains of the KCCQ-12.
“Key goals in managing chronic heart failure are to improve patients’ symptoms and quality of life,” said CHAMP-HF Chair Gregg C. Fonarow. “These findings in a real world setting are important because they suggest that taking sacubitril/valsartan may help patients achieve these goals.”
“In addition to the already reported reduction in risk of cardiovascular death and heart failure hospitalization in HFrEF patients treated with Entresto, we now show its potential to improve patient-reported health status,” said Shreeram Aradhye, Chief Medical Officer and Global Head, Medical Affairs, Novartis Pharmaceuticals. “What we find most encouraging is that both our Entresto clinical program and now this real world analysis have shown health status benefits as measured by KCCQ.”